Clovis Oncology (CLVS) Posts Smaller Q2 Loss, Sales Beat

Clovis Oncology (NASDAQ: CLVS) reported Q2 EPS of ($1.29), $0.84 better than the analyst estimate of ($2.13). Revenue for the quarter came in at $14.62 million versus the consensus estimate of $13.31 million.

For earnings history and earnings-related data on Clovis Oncology (CLVS) click here.

You May Also Be Interested In

• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• Bimergen Energy Corporation (BESS) Reports Q2 EPS of $0.22
• Smith-Midland Corporation (SMID) Tops Q2 EPS by 26c